Limits...
The preparation of 3,5-dihydroxy-4-isopropylstilbene nanoemulsion and in vitro release.

Zhang Y, Gao J, Zheng H, Zhang R, Han Y - Int J Nanomedicine (2011)

Bottom Line: The nanoemulsion was also determined by FT-Raman spectroscopy.The DHPS nanoemulsion demonstrated good stability and stable physical and chemical properties.The nanoemulsion dramatically improved the transdermal release of DHPS (from 8.02 μg · cm(-2) to 273.15 μg · cm(-2)) and could become a favorable new dosage form for DHPS.

View Article: PubMed Central - PubMed

Affiliation: College of Chemistry and Enviromental Science, Hebei University, Baoding, China.

ABSTRACT
We have reported a novel procedure to prepare 3,5-dihydroxy-4-isopropylstilbene (DHPS) nanoemulsion, using a low-energy emulsification method. Based on the phase diagram, the optimum prescription of nanoemulsion preparation was screened. With polyoxyethylenated castor oil (EL-40) as the surfactant, ethanol as the co-surfactant, and isopropyl myristate (IPM) as the oil phase, the DHPS nanoemulsion was obtained with a transparent appearance, little viscosity, and spherically uniform distribution verified by transmission electron microscopy and laser scattering analyzer. The nanoemulsion was also determined by FT-Raman spectroscopy. The DHPS nanoemulsion demonstrated good stability and stable physical and chemical properties. The nanoemulsion dramatically improved the transdermal release of DHPS (from 8.02 μg · cm(-2) to 273.15 μg · cm(-2)) and could become a favorable new dosage form for DHPS.

Show MeSH
The ternary phase diagram under different proportion condition.Abbreviations: L1, W/O nanoemulsion area; L2, O/W nanoemulsion area; G, viscous area; G1, viscous but opacified area; G2, viscous but clarified area; E, ordinary emulsion area; W, the turbid area.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3107722&req=5

f3-ijn-6-649: The ternary phase diagram under different proportion condition.Abbreviations: L1, W/O nanoemulsion area; L2, O/W nanoemulsion area; G, viscous area; G1, viscous but opacified area; G2, viscous but clarified area; E, ordinary emulsion area; W, the turbid area.

Mentions: As Figure 3 shows, when Km = 6:1, a small amount of oil (5.2%) can be emulsified and the nanoemulsion region is faint. As the Km decreases, the nanoemulsion region increases, further increasing the proportion of co-surfactant (Km = 3:1); the nanoemulsion region increases to a large scale and a considerable amount of oil (15.6%) can be emulsified. When Km decreases to 1.5:1, the co-surfactant occupies a bigger ratio and the nanoemulsion cannot be formed. Taking a comprehensive view of the nanoemulsion region, and the lower amount of Smix (surfactant/co-surfactant) used in this system, we finally selected the Km ratio as 3:1, and the ratio of Smix to oil as 3:7. Nanoemulsions prepared with this formulation were further studied for stability and potential clinical application. Under this optimized ratio, the prepared DHPS nanoemulsions with different mass ratios of Smix to oil were photographed and are shown in Figure 4.


The preparation of 3,5-dihydroxy-4-isopropylstilbene nanoemulsion and in vitro release.

Zhang Y, Gao J, Zheng H, Zhang R, Han Y - Int J Nanomedicine (2011)

The ternary phase diagram under different proportion condition.Abbreviations: L1, W/O nanoemulsion area; L2, O/W nanoemulsion area; G, viscous area; G1, viscous but opacified area; G2, viscous but clarified area; E, ordinary emulsion area; W, the turbid area.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3107722&req=5

f3-ijn-6-649: The ternary phase diagram under different proportion condition.Abbreviations: L1, W/O nanoemulsion area; L2, O/W nanoemulsion area; G, viscous area; G1, viscous but opacified area; G2, viscous but clarified area; E, ordinary emulsion area; W, the turbid area.
Mentions: As Figure 3 shows, when Km = 6:1, a small amount of oil (5.2%) can be emulsified and the nanoemulsion region is faint. As the Km decreases, the nanoemulsion region increases, further increasing the proportion of co-surfactant (Km = 3:1); the nanoemulsion region increases to a large scale and a considerable amount of oil (15.6%) can be emulsified. When Km decreases to 1.5:1, the co-surfactant occupies a bigger ratio and the nanoemulsion cannot be formed. Taking a comprehensive view of the nanoemulsion region, and the lower amount of Smix (surfactant/co-surfactant) used in this system, we finally selected the Km ratio as 3:1, and the ratio of Smix to oil as 3:7. Nanoemulsions prepared with this formulation were further studied for stability and potential clinical application. Under this optimized ratio, the prepared DHPS nanoemulsions with different mass ratios of Smix to oil were photographed and are shown in Figure 4.

Bottom Line: The nanoemulsion was also determined by FT-Raman spectroscopy.The DHPS nanoemulsion demonstrated good stability and stable physical and chemical properties.The nanoemulsion dramatically improved the transdermal release of DHPS (from 8.02 μg · cm(-2) to 273.15 μg · cm(-2)) and could become a favorable new dosage form for DHPS.

View Article: PubMed Central - PubMed

Affiliation: College of Chemistry and Enviromental Science, Hebei University, Baoding, China.

ABSTRACT
We have reported a novel procedure to prepare 3,5-dihydroxy-4-isopropylstilbene (DHPS) nanoemulsion, using a low-energy emulsification method. Based on the phase diagram, the optimum prescription of nanoemulsion preparation was screened. With polyoxyethylenated castor oil (EL-40) as the surfactant, ethanol as the co-surfactant, and isopropyl myristate (IPM) as the oil phase, the DHPS nanoemulsion was obtained with a transparent appearance, little viscosity, and spherically uniform distribution verified by transmission electron microscopy and laser scattering analyzer. The nanoemulsion was also determined by FT-Raman spectroscopy. The DHPS nanoemulsion demonstrated good stability and stable physical and chemical properties. The nanoemulsion dramatically improved the transdermal release of DHPS (from 8.02 μg · cm(-2) to 273.15 μg · cm(-2)) and could become a favorable new dosage form for DHPS.

Show MeSH